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Legally ﬂawed, scientiﬁcally problematic, potentially harmful: 
The UK Psychoactive Substance Bill 
Introduction 
This journal has often analysed legislation in the ﬁeld of drug 
policy. Rarely has it discussed a proposed law that has such deep 
problems in its legal and scientiﬁc bases. The Psychoactive 
Substances Bill, which is currently proceeding through the UK 
Parliament, will (if enacted) create a ‘blanket ban’ on the 
production, importation, exportation and supply of all psychoac- 
tive substances for human consumption, except for those that are 
speciﬁcally exempted. The Bill provides for a range of civil and 
criminal penalties, with a maximum seven-year prison sentence. 
This editorial will discuss some of the legal ﬂaws and scientiﬁc 
problems that the Bill displays. It will consider some of the likely 
adverse consequences of the legislation, alongside the possibility 
of positive effects. We argue that the extraordinarily broad scope of 
the Bill, its exclusion of any consideration of harms caused by the 
substances that it bans, and the difﬁculty of deﬁning these 
substances by ‘psychoactivity’ mean that the legislation bans too 
wide a range of substances and activities and will be difﬁcult to 
enforce. Such enforcement may also be disproportionate to the 
harms caused by some of the banned substances and activities, 
including ‘social supply’. The Bill is also likely to lead to a number of 
unintended consequences due to displacement between sub- 
stances and markets. We provide examples of such displacement 
in the cases of the 2010 mephedrone ban and of more recent action 
against retail NPS outlets in Blackburn. We conclude with some 
unavoidably pessimistic predictions. 
Legal issues 
The Bill was an ideal opportunity for Parliament to pursue (or to 
trial) a new approach to drug control. It might have adopted a 
licensing regime modelled on New Zealand’s Psychoactive Sub- 
stances Act 2013 or as proposed by the European Commission 
(‘Regulation of the European Parliament and of the Council’, 2013/ 
0305; 17 September 2013). Instead, the government has followed 
countries such as Ireland and Poland in opting for a blanket ban. In 
the Bill, as it passed through the House of Lords, a ‘psychoactive 
substance’ is one that has a ‘psychoactive effect’, deﬁned as an 
effect on a person’s ‘mental functioning or emotional state’. This 
includes an extraordinarily broad range of substances. They are not 
limited to new psychoactive substances (NPS), as had been 
proposed by the government convened expert panel (The New 
Psychoactive Substances Expert Panel, 2014). Nor are they limited 
to substances which may lead to dependence or ‘signiﬁcant’ 
changes in functioning, as is the case with the Irish legislation. The 
Bill does specify a list of speciﬁcally exempted substances. These 
include alcohol, caffeine, nicotine, food (unless containing an 
unauthorised psychoactive ingredient that is not naturally 
occurring), medicines, substances controlled under the Misuse 
of Drugs Act 1971 (MDA) and other substances that may be placed 
on the exempted list by the Home Secretary in future. The number 
of substances that ﬁt the deﬁnition of psychoactivity but do not ﬁt 
into this list of exemptions is probably unknowable, but will be 
very large indeed. 
The Bill does not – unlike the MDA – directly criminalise the 
simple possession of a psychoactive substance. Given the lack of 
evidence that criminalisation of possession reduces levels of drug 
use or harm (Home Ofﬁce, 2014; Stevens, 2011), this is welcome. 
But the Bill does criminalises the production, supply (including 
offers and possession with intent to supply), importation and 
exportation, of a psychoactive substance. The offences of 
producing, importing or exporting a  psychoactive  substance can 
be committed even if the substance was intended to be for 
personal use. Under the Bill, a person importing a ‘psychoactive 
substance’ via a foreign website would commit a criminal offence, 
even if it were only for their own use, as would a person who 
passes such substance to another person, even without payment. 
Such ‘social supply’ occurs frequently in the social world of 
recreational substance use and has the potential to make 
criminals of many young people. The government has justiﬁed 
its stance so as to avoid ‘an open invitation for individuals to 
import numerous small quantities, which they could then 
combine together for onward supply’ (Hansard, 14 July 2015, 
HL, col. 539). This overlooks the trust that is routinely placed in 
investigators and courts to correctly identify persons engaged in 
the chain of supply for retail. It also ignores the probability that a 
criminal record would do more harm to many of these young 
people than would their actions in passing on substances which 
may be of minimal harm. 
In addition to the absence of an offence of possession, another 
positive aspect of the Bill (relative to the MDA) is the inclusion of a 
mental ingredient in each of the ‘trafﬁcking’ offences rather than 
the clumsy defences provided by section 28 of the MDA. Even so, 
we would argue that the Bill still goes too far in extending the reach 
of criminal liability, considering the scientiﬁc challenges in 
identifying psychoactivity and the potential lack of harm from 
some such substances, as discussed below. 
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Problems in psychopharmacology 
As noted above, the Bill does not make harm or potential for 
dependence a criterion by which a psychoactive substance is either 
included or exempted from its scope. This is a substantial change 
from the MDA, which seeks to control drugs ‘‘. . .which are being 
or. . .likely to be misused and of which the misuse is having 
or. . .capable of having harmful effects sufﬁcient to constitute a social 
problem’’ (s.1(2); emphasis added). Thus, there is no ‘threshold’ of 
harm beyond which psychoactive substances are brought within 
the terms of the Bill. The Bill also fails to recognise that even 
substances which produce profound changes in mental states do 
not necessarily lead to serious adverse outcomes (e.g. Johansen & 
Krebs, 2015; Studerus, Kometer, Hasler, & Vollenweider, 2011). 
The exclusion of the concept of harm from the Bill is intended to 
avoid the need for lengthy deliberation on potential harms before a 
substance is banned; this was the rationale provided by the expert 
panel (The New Psychoactive Substances Expert Panel, 2014). 
However, that panel also recognised the possibility of a future 
substance being discovered that is minimally harmful and is of 
enough clinical, commercial, cognitive enhancing, or (dare we say) 
recreational value that legal supply would be warranted. 
Accordingly, the panel recommended a ‘safety valve’ provision 
through which such substances could be placed on the exempted 
list (Ibid: 38). This provision has not been included in the Bill. 
Without it, legislative control is irrevocably decoupled from any 
assessment of the risk of harm. This means that the discovery and 
fulﬁlment of potential beneﬁts from psychoactive substances will 
be impeded. It also means that people may face disproportionate 
sanctions for offences relating to substances that may be of very 
little harm. 
The simple focus on ‘psychoactivity’ in the Bill is also 
problematic. Whilst it is understandable that legislators might be 
concerned about the emergence of NPS such as synthetic cannabi- 
noid receptor agonists (Seely, Lapoint, Moran, & Fattore, 2012), it is 
questionable whether many of the non-exempted psychoactive 
substances that are sold in health food shops (e.g. lavender oil) or 
garden centres (e.g. morning glory seeds) pose a public health threat 
(Shulgin & Perry, 2002; Woelk & Schlafke, 2010). 
Established recreational substances, some of which have a 
history of use over several centuries without having been 
controlled under the MDA (e.g. nitrous oxide), are included in 
the Bill. In addition to its well established use as an anaesthetic, 
nitrous oxide is also an EU approved food additive (E942) and so 
manufacture and sale would be permitted under the Bill for some 
uses. This is one example of the inherent difﬁculties in attempting 
to ban everything that may be psychoactive and then creating 
exemptions, rather than controlling substances by their pharma- 
ceutical or botanical name or molecular structure or risk proﬁle, as 
the MDA usually does. 
It is not currently possible to predict whether a substance will 
have a psychoactive effect (as deﬁned by the Bill) simply by 
examining its chemical structure. Analysis of pharmacological 
proﬁles through rapid in vitro screening techniques may allow for 
qualitative comparison with previously characterised drugs, but 
this provides no insight into important quantitative pharmacolog- 
ical parameters. The only true test of human psychoactivity is 
evidence generated from clinical studies, but licensing require- 
ments, adherence to good manufacturing process standards and 
ethical board review means that characterisation is not realisti- 
cally feasible for more than a small number of new drugs. 
Salvia divinorum, a plant hallucinogen, shows the potential 
difﬁculties of the Bill’s approach. The properties of Salvia have been 
studied for many years, but if it were newly emerging onto the market 
it would be difﬁcult to make predictions about its psychoactive 
effects. In contrast to classic serotonergic hallucinogens, its primary 
active constituent – salvinorin A – possesses unique pharmacology at 
kappa opioid receptors (Grundmann, Phipps, Zadezensky, & Butter- 
weck, 2007), is not self-administered by rats given access to it (Serra 
et al., 2015), is aversive in mice (Zhang, Butelman, Schlussman, Ho, & 
Kreek, 2005) and is not detected by simple pre-clinical behavioural 
assays of hallucinogen-like activity (Halberstadt, 2015). Without 
evidence from clinical or robust naturalistic studies, psychoactivity 
and human use of salvinorin A would be difﬁcult to predict by 
comparison with existing drugs. It would be very difﬁcult indeed for a 
prosecutor to prove that a supplier, producer or importer knew, or 
even ought to have known, that such a substance was psychoactive. 
These legal and psychopharmacological problems will make it 
difﬁcult to bring successful prosecutions. The intended use of the 
Bill to shut down the legal trade in NPS also has predictable adverse 
effects on the use and harms of psychoactive substances in general. 
Displacement effects 
The government assumes that the Bill will reduce the supply of 
all non-exempted psychoactive substances (Home Ofﬁce, 2015). 
However, as we can see with the example of mephedrone (which 
was placed under the MDA in 2010), if any psychoactive substance 
is banned there is the potential for displacement of use to other, 
potentially more harmful substances. Before 2010, mephedrone’s 
appeal to users related to easy availability and high purity at a time 
of low purity of cocaine and MDMA (Measham, Moore, Newcombe, 
& Welch, 2010). After prohibition, many users stopped taking 
mephedrone either because they did not like its effects enough to 
seek out a street dealer, or because they sought out alternative 
stimulants controlled under Class A of the MDA, some of which 
were then increasing in purity (Measham & Newcombe, 2015; 
Moore, Dargan, Wood, & Measham, 2013). While the demand for 
various forms of intoxication continues, banning the trade in 
currently non-controlled psychoactive substances may have the 
effect of pushing users back to potentially harmful substances that 
have already been prohibited under the MDA or to other 
intoxicants (such as volatile substances, cheap alcohol or diverted 
prescription medications). 
The Bill will enable the closure of retail outlets for NPS, 
sometimes known as ‘headshops’. But closing headshops may not, 
in practice, actually reduce harms. The English town of Blackburn 
provides an example of how closing headshops while demand for 
NPS continues may increase risks for users. When the local 
authority took action against high street headshops, NPS sales 
were displaced initially to out of town retail outlets, and then, 
within days, to an informal street trade. The same users bought the 
same synthetic cannabinoids from an existing street dealer of Class 
A drugs. He had bought up the headshop stock and split labelled 
commercial packages into smaller, unlabelled ‘deals’ in ‘baggies’ 
(small bags used for illegal drug sales) in order to promote sales 
(Linnell, Measham, & Newcombe, 2015). Some headshops 
appeared to have operated some safer practices, such as not 
serving customers aged under 18, selling labelled products with 
listed ingredients and not offering promotions. The street dealer, in 
contrast, employed a team of ‘runners’ who delivered synthetic 
cannabinoids to customers of any age across the town. His range of 
promotional offers was reported to include credit, free cigarettes 
and cigarette papers and exchanging used clothes for NPS at a 
‘clothes for cash’ shop. The users he served were amongst the most 
vulnerable people in the area; often young, unemployed, homeless, 
recently released from prison and known to social services. 
Possible positive outcomes? 
Supporters of the Bill have claimed that it will have positive 
outcomes through the precautionary banning of all psychoactive 
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substances that are not considered suitable for recreational human 
consumption. It is also claimed that the legislation will ‘send a 
message’ to potential users of ‘legal highs’ that these substances 
are not safe. Both these mechanisms, it is claimed, will have the 
effect of reducing the use of NPS and therefore will prevent harm; 
the Home Ofﬁce (2015) estimates that the Bill will lead to 12 fewer 
deaths from NPS each year. 
The ﬁrst, precautionary mechanism may indeed have the effect 
of restricting the ease of availability of NPS if it substantially 
reduces the legal trade, as appears to have happened in Ireland. But 
there is little evidence to suggest that NPS use has actually declined 
in Ireland (what little evidence we do have suggests that it has not 
fallen since the ban (TNS Political & Social, 2014)). Deaths from NPS 
regrettably continue in that country (EMCDDA, 2015a). 
The second mechanism – using the law to raise awareness of 
the dangers of NPS and so reduce use – relies on two assumptions: 
that people use unbanned NPS because they think they are safer 
than illicit drugs; and that the law is an effective channel for 
communicating with the public. However, evidence from the ﬁeld 
suggests that many young people are already aware that ‘legal 
highs’ may be more dangerous than currently banned substances 
(Bradley, 2015). And a Parliamentary committee has already 
found that drug bans are not effective in ‘sending messages’ to the 
public (House of Commons Science & Technology Committee, 
2006). 
Even if the Bill does lead to a reduction in the availability and 
use of NPS, this will not reduce overall rates of drug-related harm if 
it pushes people towards more dangerous forms of buying and 
using NPS and the already prohibited substances (MacCoun, 
Reuter, & Schelling, 1996). It will be very difﬁcult to achieve a 
reduction of 12 deaths related to currently uncontrolled psycho- 
active substances, given that this would represent a two thirds 
reduction of the deaths in which such substances were implicated 
in 2014 (ONS, 2015). Even if it were achieved, this would be 
difﬁcult to discern amongst the thousands of deaths that are 
recorded as drug-related in the UK each year. Many more of them 
could be prevented by the implementation of evidence-based 
measures which the government is failing to permit or fully fund, 
such as supervised injecting sites or take-home naloxone and 
training provision (EMCDDA, 2015b; Potier, Lapre  ´vote, Dubois- 
Arber, Cottencin, & Rolland, 2014). 
Conclusion 
Parliament may take the view that if headshops are eliminated 
in the UK that this is ‘success’. The less visible truths may be 
distinctly more unpalatable. Here, we risk making some predic- 
tions about the Bill’s likely effects. 
The threat of civil and criminal penalties may be enough to 
close down legal retail outlets without the need to go to court. 
However, prosecutions that are brought will be costly and 
problematic due to the difﬁculty in proving psychoactivity. The 
use of NPS, and related harms, will continue. We are particularly 
concerned about the potential of new patterns of high frequency 
injecting of stimulant NPS to emerge, as has been seen in other 
countries that have banned this trade (e.g. Poland and Hungary) 
and in some areas of the UK after the ban on mephedrone 
(EMCDDA, 2013; PHE, 2014). If the police and local authorities 
focus on closing headshops without simultaneously taking steps 
to reduce demand, then it is probable that the trade will be 
displaced to illegal dealers whose sales practices may increase 
harms. We are likely to see a merger of the markets for NPS and the 
more traditional illicit drugs, both on the street and online. The 
harms of these markets and of their control will continue to be 
concentrated among the most vulnerable and disadvantaged 
groups. 
We hope to be proved wrong in these predictions. The 
government may amend the legislation as  it passes  through the 
House of Commons to narrow the deﬁnition of the substances it 
covers to include, for example, only synthetic substances. This 
would reduce some (but not all) of the problems relating to the 
deﬁnition. It would not allay our fears about other unintended 
consequences, including displacement. We see the legal and 
scientiﬁc ﬂaws in the Bill in its current form to be so great, and 
the potential for adverse consequences to be so clear, that we 
call for readers of this journal to participate in the debate in 
order to reduce harms, both of NPS and of this legislation. 
Note 
This editorial was revised on 15th October 2015 and does not 
take into account any subsequent amendments to the Psychoactive 
Substances Bill. Alex Stevens, Fiona Measham and Harry Sumnall 
are members of the UK Advisory Council on the Misuse of Drugs 
(ACMD). We are writing here in our capacity as independent 
academics/practitioners. The views expressed in this article do not 
represent those of the ACMD. 
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